ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Functional Chain Engineering in MOFs: Balancing Pore Size and Affinity for Noble Gas Separation.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The efficient separation of Xe from Kr requires adsorbents with optimized pore environments that maximize van der Waals interactions with Xe atoms. To achieve this, a series of five metal-organic frameworks (MOFs) are synthesized using a mixed-ligand strategy that systematically incorporates bulky C8 alkoxy substituents into the IRMOF-1 framework through varying ratios of terephthalic acid (BDC) and 2,5-bis(octyloxy)-1,4-benzenedicarboxylic acid (C8BDC). Increasing the C8BDC content progressively reduces the pore size, and ML-80C8 (20% BDC and 80% C8BDC) provides the optimal pore environment for selective Xe adsorption. ML-80C8 exhibits the best Xe/Kr separation performance, achieving a high Xe uptake of 0.96 mmol g
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.